Sharps Technology enters 5-year deal for 520M syringes, selling out EU facility capacity

Sharps Technology Inc.

5-year supply agreement with Stericare Solutions for 520M units of 10mL SoloGard syringes.
Expected revenue exceeds $50M; first delivery targeted November 2024.
Agreement sells out current manufacturing capacity for 10mL SoloGard at EU facility.
Customer is a U.S. supplier of medical saline/water products; evaluation triggered by FDA recalls and Chinese syringe tariffs.
Q4 2024 revenue ramp begins; company to expand EU facility for future growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.